Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Yuste-Checa

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Human Molecular Genetics|January 26, 2011
SHOX interacts with the chondrogenic transcription factors SOX5 and SOX6 to activate the aggrecan enhancerMiriam Aza-Carmona, Debbie J Shears, Patricia Yuste-Checa, et al.
Nature Communications|February 2, 2023
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular systemItika Saha, Patricia Yuste-Checa, Miguel Da Silva Padilha, et al.
Epilepsia|January 29, 2013
Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic optionBelén Pérez, Luis González Gutiérrez-Solana, Alfonso Verdú, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Human Molecular Genetics|January 26, 2011
SHOX interacts with the chondrogenic transcription factors SOX5 and SOX6 to activate the aggrecan enhancerMiriam Aza-Carmona, Debbie J Shears, Patricia Yuste-Checa, et al.
Nature Communications|February 2, 2023
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular systemItika Saha, Patricia Yuste-Checa, Miguel Da Silva Padilha, et al.
Epilepsia|January 29, 2013
Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic optionBelén Pérez, Luis González Gutiérrez-Solana, Alfonso Verdú, et al.
Pageof 2